Skip to main content
Premium Trial:

Request an Annual Quote

HealthLinx Obtains UK Patent for OvPlex Ovarian Cancer Diagnostic


Australian diagnostics firm HealthLinx said this week it has been granted a UK patent for its protein biomarker ovarian cancer diagnostic OvPlex.

The patent is the first granted to the company for its OvPlex test, which uses a five-protein panel to aid early diagnoses of ovarian cancer in symptomatic women.

HealthLinx launched OvPlex in Australia in October 2008, but temporarily suspended sales in September 2009 when its domestic distributor, ARL Pathology, was acquired by the healthcare provider Healthscope. It relaunched Australian sales of the test through Healthscope this June and also brought the test to market in the UK in February and Singapore in July (PM 12/03/2011).

HealthLinx is now looking to add another two proteins to the OvPlex's panel in hopes of improving its performance. According to the company, initial results from the first stage of an ongoing 1,150-subject study suggest that adding the two new proteins – AGR2 and HTX010 – could increase the test's accuracy (PM 12/17/2010).

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.